Stengone Carmine N. (CIK 1861519) reported 11 SEC Form 4 insider transactions across 1 companies over the past 18 months (most recent 2026-07-08). Recent activity: Buy CTNM (2,500 shares), Sell CTNM (2,500 shares), Buy CTNM (7,500 shares), Buy CTNM (2,500 shares), Sell CTNM (10,000 shares). Source: SEC Form 4.
| Date | Company | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-07-08 | Contineum Therapeutics, Inc. (CTNM) | CEO and President | Buy | 2,500 | $2,525 |
| 2026-07-08 | Contineum Therapeutics, Inc. (CTNM) | CEO and President | Sell | 2,500 | $40,000 |
| 2026-07-01 | Contineum Therapeutics, Inc. (CTNM) | CEO and President | Buy | 7,500 | $7,575 |
| 2026-07-01 | Contineum Therapeutics, Inc. (CTNM) | CEO and President | Buy | 2,500 | $3,150 |
| 2026-07-01 | Contineum Therapeutics, Inc. (CTNM) | CEO and President | Sell | 10,000 | $160,080 |
| 2026-02-26 | Contineum Therapeutics, Inc. (CTNM) | CEO and President | Buy | 4,400 | $5,544 |
| 2026-02-26 | Contineum Therapeutics, Inc. (CTNM) | CEO and President | Sell | 4,400 | $70,488 |
| 2026-02-26 | Contineum Therapeutics, Inc. (CTNM) | CEO and President | Buy | 2,700 | $3,402 |
| 2026-02-26 | Contineum Therapeutics, Inc. (CTNM) | CEO and President | Sell | 2,700 | $43,254 |
| 2026-02-13 | Contineum Therapeutics, Inc. (CTNM) | CEO and President | Buy | 400 | $504 |
| 2026-02-13 | Contineum Therapeutics, Inc. (CTNM) | CEO and President | Sell | 400 | $6,400 |
Source: SEC Form 4 filings · as of 2026-07-08